The U.S. Food and Drug Administration (FDA) reported this Friday that the XBB.1.5 variant of the coronavirus is likely to be resistant to the British laboratory AstraZeneca’s drug for COVID-19, Evusheld. bottom.
According to the FDA, the UK pharmaceutical company’s antiviral drugs may not offer protection against the onset of COVID-19 for individuals who were given COVID-19 and later exposed to the new variant.
Evusheld was the last antibody in its class still approved in the United States to prevent infection in high-risk people. This is because the remaining drugs were excluded as they likely do not protect against new variants.
Antibody therapy is essential for treating and preventing disease among the approximately 7 million immunocompromised Americans who may be less responsive to vaccines and antiviral drugs.
However, as the COVID-19 virus mutated, we removed the antibodies from the market one by one.
Currently, according to FDA data, XBB.1.5 (which is derived from Ómicron) accounts for 28% of all variants in circulation in the United States.
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus explained that the International Health Organization is assessing a rapid increase in XBB.1.5 variants in both the United States and 24 other countries.
Tedros is “extremely concerned” about the current epidemiological situation of COVID-19 “due to both its intense transmission in different parts of the world and its rapidly spreading recombinant subvarieties.”
In this regard, he assured that the WHO is “closely monitoring and assessing the risk of this subspecies and will report on any new data obtained accordingly.”